Drug Trial Radar · NCT07541170
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 6, 2026
Primary completion
Jan 31, 2032
Study completion Mar 31, 2035
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
DivarasibDrug
Divarasib will be administered orally as per the schedule specified in the respective arm.
PembrolizumabDrug
Pembrolizumab will be administered as either a 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) or 395 mg subcutaneous (SC) injection Q3W, for up to 13 cycles (1 cycle = 21 days).
NivolumabDrug
Nivolumab will be administered as either a 480 mg IV infusion, every 4 weeks (Q4W) or 1200 mg SC injection Q4W, for up to 13 cycles (1 cycle = 28 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (DFS), as Determined by the InvestigatorTime frame: From randomization to disease recurrence or death from any cause (Up to approximately 5 years)
Locations
104 sites in 19 countries. Site status is shown where the registry gives one.
Community Cancer Institute (CCI)
Clovis, California · Recruiting
Bay Pines VA Healthcare System
Bay Pines, Florida · Recruiting
Piedmont Cancer Institute, PC
Atlanta, Georgia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Profound Research, LLC
Farmington Hills, Michigan · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Cancer Care Specialists
Reno, Nevada · Recruiting
San Juan Oncology Associates
Farmington, New Mexico · Recruiting
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Baptist Clinical Research Institute
Memphis, Tennessee · Recruiting
Instituto Argentino de Diagnóstico y Tratamiento- IADT
Capital Federal, Argentina · Recruiting
Hospital Britanico
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Clinica Adventista Belgrano
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Hospital Privado De Comunidad
Mar del Plata, Argentina · Recruiting
Sanatorio de la Mujer
Rosario, Santa Fe Province, Argentina · Recruiting
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium · Recruiting
CHU HELORA - Hôpital de Mons - Site Kennedy
Mons, Belgium · Recruiting
Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil · Recruiting
Cenantron - Centro Avancado de Tratamento Oncologico
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, Brazil · Recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
McGill University Health Center
Montreal, Quebec, Canada · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
The First Hospital of Jilin University
Changchun, China · Recruiting
The First People's Hospital of Foshan
Foshan, China · Recruiting
Guangdong General Hospital
Guangzhou, China · Recruiting
The Second Affiliated Hospital of Zhejiang University College
HangzhouZhejiang, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Nanjing First Hospital
Nanjing, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, China · Recruiting
Taizhou Hospital Of Zhejiang Province
Taizhou, China · Recruiting
Tianjin Cancer Hospital
Tianjin, China · Recruiting
Anhui Provincial Hospital(The First Affiliated Hospital of USTC)
Hefei, Anhui, China · Recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.